Home / Business and Economy / Concord Biotech FDA Approval Boosts US Market
Concord Biotech FDA Approval Boosts US Market
2 Jun
Summary
- Concord Biotech secured US FDA approval for Mycophenolate Mofetil.
- The drug is used to prevent organ rejection in transplant patients.
- The US market for this drug is estimated at $30 million annually.
Concord Biotech announced on June 2, 2026, that it has received approval from the US Food and Drug Administration (FDA) for its Mycophenolate Mofetil for oral suspension USP, 200 mg/mL. This medication is an antimetabolite immunosuppressant vital for preventing organ rejection in adult and pediatric patients undergoing kidney, heart, or liver transplants. The drug is typically administered alongside other immunosuppressive treatments.
The US market for Mycophenolate Mofetil is valued at approximately $30 million, according to company-cited market estimates. This FDA approval is a key component of Concord Biotech's expansion strategy, poised to enhance its product portfolio and solidify its position within the United States. The company anticipates this development will support its long-term growth trajectory in both the US and international markets.
In separate financial news, Concord Biotech reported a 36.8% decrease in its fourth-quarter earnings, with net profit falling to ₹88.8 crore. Revenue from operations also saw a decline of 24.1% year-on-year. The board has proposed a dividend of ₹7.55 per equity share for FY26, subject to shareholder approval, with a record date set for July 24, 2026.
